Background The optimal antithrombotic therapy for patients with atrial fibrillation undergoing
percutaneous coronary intervention is a topic of debate. We aimed at defining the efficacy …

Aims To investigate the safety and efficacy of double vs. triple antithrombotic therapy (DAT
vs. TAT) in patients with atrial fibrillation (AF) and acute coronary syndrome or who …

Aims Safety and efficacy of antithrombotic regimens in patients with atrial fibrillation (AF)
undergoing percutaneous coronary intervention (PCI) may differ based on clinical …

Aims Recently, three randomized trials reported that dual antithrombotic treatments (DATs)
including non-vitamin K antagonist oral anticoagulants (NOACs) and a P2Y12 inhibitor …

Background: Our study aims to perform a meta-analysis of benefits and risks associated with
the use of non-vitamin K oral anticoagulants (NOAC) versus vitamin K antagonists (VKA) in …

Aims Double or triple antithrombotic therapy (DAT/TAT) including or excluding aspirin in
association with oral anticoagulant and P2Y12 inhibitor are currently two available options …

Importance The antithrombotic treatment of patients with atrial fibrillation (AF) and coronary
artery disease, in particular with acute coronary syndrome (ACS) and/or percutaneous …

In patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI), the
effectiveness and safety of dual compared with triple antithrombotic therapy are a matter of …

Most patients with atrial fibrillation (AF) and risk factors for stroke require oral anticoagulation
(OAC) to decrease the risk of stroke or systemic embolism. This is now best achieved with …

Aims Of patients with atrial fibrillation (AF), approximately 10% undergo percutaneous
coronary intervention (PCI). We studied the safety and efficacy of dual vs. triple …